No Data
No Data
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Express News | First Patient Enrollment in the U.S. - a Milestone for the Global Multi-Center Phase Ⅲ Clinical Trial of Telitacicept for Myasthenia Gravis
RemeGen Co. Ltd. Schedules Crucial Board Meeting
Remegen (09995.HK) is planning to hold a board of directors meeting on August 16 to approve the mid-term performance.
Remegen (09995.HK) announced that the Board of Directors will hold a meeting on Friday, August 16, 2024 to consider and approve the interim performance of the company and its subsidiaries, ending on June 30, 2024.
REMEGEN: DATE OF BOARD MEETING
Hong Kong stocks fluctuate | Remegen (09995) rose more than 3%, and innovative drug Taitsipol for the treatment of myasthenia gravis in Phase III clinical trials achieved the first patient in the United States to be enrolled.
Remegen (09995) rose more than 3%, rising 3.25% to HK$14.62 as of press time, with a turnover of HK$8.3875 million.
No Data